

University of Groningen

## **Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity**

Heida, Anke; Knol, Mariska; Kobold, Anneke Muller; Bootsman, Josette; Dijkstra, Gerard; van Rheeën, Patrick F

*Published in:*  
Clinical Gastroenterology and Hepatology

*DOI:*  
[10.1016/j.cgh.2017.06.007](https://doi.org/10.1016/j.cgh.2017.06.007)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2017

[Link to publication in University of Groningen/UMCG research database](#)

### *Citation for published version (APA):*

Heida, A., Knol, M., Kobold, A. M., Bootsman, J., Dijkstra, G., & van Rheeën, P. F. (2017). Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity. *Clinical Gastroenterology and Hepatology*, 15(11), 1742-+. <https://doi.org/10.1016/j.cgh.2017.06.007>

### **Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### **Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



# Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity

Anke Heida,<sup>\*</sup> Mariska Knol,<sup>\*</sup> Anneke Muller Kobold,<sup>‡</sup> Josette Bootsman,<sup>\*</sup> Gerard Dijkstra,<sup>§</sup> and Patrick F. van Rhee<sup>en</sup>\*

<sup>\*</sup>Department of Paediatric Gastroenterology, Hepatology and Nutrition, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands; <sup>‡</sup>Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; <sup>§</sup>Department of Gastroenterology, Hepatology and Nutrition, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

## BACKGROUND & AIMS:

An increasing number of physicians use repeated measurements of stool calprotectin to monitor intestinal inflammation in patients with inflammatory bowel diseases (IBDs). A lateral flow-based rapid test allows patients to measure their own stool calprotectin values at home. The test comes with a software application (IBDoc; Bühlmann Laboratories AG, Schönenbuch, Switzerland) that turns a smartphone camera into a results reader. We compared results from this method with those from the hospital-based reader (Quantum Blue; Bühlmann Laboratories AG) and enzyme-linked immunosorbent assay (ELISA) analysis.

## METHODS:

In a single-center comparison study, we asked 101 participants (10 years of age or older) in the Netherlands to perform the IBDoc measurement on stool samples collected at home, from June 2015 to October 2016. Participants then sent the residual extraction fluid and a fresh specimen from the same bowel movement to our pediatric and adult IBD center at the University Medical Center Groningen, where the level of calprotectin was measured by the Quantum Blue reader and ELISA analysis, respectively. The primary outcome was the agreement of results between IBDoc and the Quantum Blue and ELISA analyses, determined by Bland-Altman plot analysis.

## RESULTS:

We received 152 IBDoc results, 138 samples of residual extraction fluid for Quantum Blue analysis, and 170 fresh stool samples for ELISA analysis. Spearman's rank correlation coefficient was 0.94 for results obtained by IBDoc vs Quantum Blue and 0.85 for results obtained by IBDoc vs ELISA. At the low range of calprotectin level (<500 µg/g), 91% of IBDoc–Quantum Blue results were within the predefined limits of agreement (±100 µg/g), and 71% of IBDoc–ELISA results were in agreement. At the high range of calprotectin level (≥500 µg/g), 81% of IBDoc–Quantum Blue results were within the predefined limits of agreement (±200 µg/g) and 64% of IBDoc–ELISA results were in agreement.

## CONCLUSIONS:

Measurements of fecal levels of calprotectin made with home-based lateral flow method were in agreement with measurements made by Quantum Blue and ELISA, as long as concentrations were <500 µg/g. For patients with concentrations of fecal calprotectin above this level, findings from IBDoc should be confirmed by another method. (Netherlands Trial Registration Number: NTR5133).

**Keywords:** Biomarker; Telemedicine; Point-of-care test; Monitoring IBD Activity.

Crohn's disease and ulcerative colitis are progressive inflammatory bowel diseases (IBDs) that may result in irreversible bowel damage. The ultimate goal of treating IBD patients is to achieve symptom control and stop disease progression to change the natural course of the disease. The desired treatment target is mucosal healing and fecal calprotectin (FC) levels correlate well with this target.<sup>1–4</sup> Asymptomatic patients whose FC

**Abbreviations used in this paper:** CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; FC, fecal calprotectin; IBD, inflammatory bowel disease.

Most current article

© 2017 by the AGA Institute. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1542-3565

<http://dx.doi.org/10.1016/j.cgh.2017.06.007>

levels drift away from the target range have an increased risk to develop a disease flare in the next 2–3 months, while repeated FC levels in the normal range suggest sustained remission.<sup>5</sup>

For 8 years we have been following children with IBDs by periodically measuring calprotectin levels in their sent-in stool samples with an enzyme-linked immunosorbent assay (ELISA). Although there is little agreement among IBD experts about the optimal cutoff points for calprotectin, in children we considered levels below 250  $\mu\text{g/g}$  as indicative for disease remission (green),<sup>6</sup> levels above 500  $\mu\text{g/g}$  as indicative for disease flare (red), and levels between 250 and 500  $\mu\text{g/g}$  provided little guidance and required short-term retesting (orange). Both physicians and patients found repeated testing of calprotectin and the traffic light color coding helpful to guide therapy, but ELISA testing is time consuming and requires a high level of expertise to perform.<sup>7</sup> Point-of-care calprotectin tests, including the Quantum Blue lateral flow immunoassay (Bühlmann Laboratories AG, Schönenbuch, Switzerland), are less time consuming, but patients are still forced to send or bring a stool sample to the hospital.<sup>8</sup> Bühlmann Laboratories AG recently developed a lateral flow–based calprotectin test and a software application (*IBDoc*) that turns an ordinary smartphone camera into a reader for quantitative measurements at home. The software application enables patients to perform a measurement and receive the result without delay, provided that there is an Internet connection available. We aimed to compare this new method with the hospital-based lateral flow reader Quantum Blue and the established ELISA method to see whether these tests agreed sufficiently for the new test to replace the old, or to use the 3 interchangeably.

## Methods

This study was a single-center prospective study, performed at the pediatric and adult IBD center at the University Medical Center Groningen (Groningen, the Netherlands).

### Participants

Eligible participants were 10 years or older with good knowledge of the Dutch language who had a smartphone that was validated to run the *IBDoc* application (Supplementary Table 1) and did not have an ileostomy. We contacted candidate participants by telephone before their next planned visit to the outpatient clinic. When patients were interested in participation, we explained the procedure during the same telephone conversation. We then sent a study package including a pictorial algorithm of the procedural steps, including instructions for sample extraction and measurement, to the patient's home.

### Stool Collection and Sampling

Participants defecated onto a stool collection sheet (included in the *IBDoc* package) held above the toilet water and collected 2 samples from the same bowel movement. The first sample was collected with the classical screw top container with spatula for ELISA measurement at the hospital laboratory. The second sample was taken with a CALEX valve extraction device (Bühlmann Laboratories AG) (Figure 1).


After performing the home test, both the CALEX valve extraction device and the screw-top container were sent in a resealable biomaterial envelope to the Department of Laboratory Medicine of the University Medical Center Groningen.

### Calprotectin Measurements

The level of calprotectin was measured 3 times (Figure 2). First, patients used the *IBDoc* application on their smartphone to read the FC level in the CALEX extraction device, using a lateral flow technique. To do so they had to place the camera above the cassette and a picture was automatically taken. The image was then analyzed and the quantitative calprotectin result was directly shown on the screen (an instruction video of the step-by-step procedure can be found at [www.ibdoc.net](http://www.ibdoc.net)). At the same time the research team received a notification that an *IBDoc* measurement was performed with a direct link to this result on a secured web portal. Second, one experienced laboratory technician in the University Medical Center Groningen, who was blinded for *IBDoc* results, used the Quantum Blue Extended Reader (Bühlmann Laboratories AG) to read the FC level in the send in CALEX extraction device, also with a lateral flow technique.<sup>9</sup> Third, the fresh stool sample was extracted in the hospital laboratory and the FC level was measured with the ELISA technique. The fresh samples were manually weighted and stored at  $-20^{\circ}\text{C}$  until analysis. The stool samples were then thawed for calprotectin measurements with the fCAL ELISA (Bühlmann Laboratories AG) on a Dynex DS2 Automated ELISA system (Alpha Labs, Easleigh, UK). The *IBDoc* and Quantum Blue tests covered a measurable range of calprotectin from 30 to 1000  $\mu\text{g/g}$ , and the ELISA tests covered a range of 40  $\mu\text{g/g}$  and above. For the analyses we therefore registered calprotectin values below 40  $\mu\text{g/g}$  as 40  $\mu\text{g/g}$  and values above 1000  $\mu\text{g/g}$  as 1000  $\mu\text{g/g}$ .

### Outcome Measures

The primary outcome was the agreement of results between *IBDoc* and the clinically accepted ELISA method, using Bland-Altman plot analysis. First, we reasoned that disagreement in the lower range of the test (ie, between 40 and 500  $\mu\text{g/g}$ ) could lead more easily to misinterpretation of disease activity than disagreement in the higher range ( $>500$   $\mu\text{g/g}$ ). We therefore used predefined acceptable



**Figure 1.** IBDoc sampling and measurement. Adapted with permission from Bühlmann Laboratories AG.<sup>23</sup>

limits of difference, which were arbitrary set at  $\pm 100 \mu\text{g/g}$  for the lower range, and  $\pm 200 \mu\text{g/g}$  for the higher range. Second, we assessed concordance of ELISA and IBDoc readings in each of the 3 FC ranges used in our clinical practice (ie,  $<250 \mu\text{g/g}$ ,  $250\text{--}500 \mu\text{g/g}$ , and  $>500 \mu\text{g/g}$ ). As there is currently no consensus among IBD experts about the range of FC associated with mucosal healing, we also reported concordance of ELISA and IBDoc readings for other frequently used dichotomous cutoffs (namely 50, 150, 200, 250, and  $300 \mu\text{g/g}$ ). Other outcome measures included agreement between patient-performed IBDoc measurements and hospital-based Quantum Blue measurements of the same extract, and an evaluation of the usability of the IBDoc method by patients.

### Quality Measurement of Scanning Methods

Prior to the study, we verified the quality of the scanning methods of both the IBDoc application on an iPhone 4S and the Quantum Blue Extended reader, as described in the [Supplementary Methods and Results](#) and [Supplementary Table 2](#).

### Sample Size Calculation

We aimed to include at least 100 paired samples in the lower range of the test (ie, between 40 and

$500 \mu\text{g/g}$ ). This sample size was based on the recommendation of Bland.<sup>10</sup>


### Statistical Analysis

Data were recorded electronically by using SPSS version 23.0 for Windows (IBM Corporation, Armonk, NY). Agreement between IBDoc and ELISA results, and between IBDoc and Quantum Blue results was compared with a Bland-Altman plot.<sup>11</sup> The Bland-Altman plot assigns the average of the old and new method on the x axis, and the difference between both on the y axis. Furthermore, we calculated the Passing-Bablok regression coefficient and Spearman rank correlations coefficient. Concordance of IBDoc and ELISA readings in each of the 3 FC ranges used in our clinical practice were presented in a scatterplot. Graphs were constructed with GraphPad Prism, version 5.04 for Windows (GraphPad Software, San Diego, CA). A *P* value below .05 was significant.

### Ethical Considerations

This study was performed according to the Declaration of Helsinki. The Medical Ethical Committee of the University Medical Center in Groningen decided that a study measuring markers in voluntary stool samples did





**Figure 2.** Study flow indicating 3 calprotectin measurements from the same bowel movement. ELISA, enzyme-linked immunosorbent assay.

not require approval according to the Dutch Medical Research Involving Human Subjects Act. All adult participants, legal guardians from pediatric participants, and children 12 years of age and older gave informed consent to use data generated by routine medical care. The data were collected and recorded by the investigators in such a manner that subjects could not be identified, directly or through identifiers linked to the subjects. This study was conducted in compliance with the Clinical Trial Agreement, the study protocol, designated Standard Operating Procedures and the international standard for clinical studies of medical devices (ISO 14155: 2011 Clinical investigation of medical devices for human subjects – Good Clinical Practice). All authors had access to the study data and reviewed and approved the final manuscript.

Results

Between June 2015 and October 2016, 306 random patients with IBD were approached by telephone, of which 211 were willing to participate. Sixty of them did not have access to a validated smartphone and were excluded from participation. The remaining 151 patients received a study package. In the end 101 patients actively participated and sampled 170 bowel movements (Figure 2). Median age of the participants was 24 (range, 10–59) years (Table 1). A total of 152 IBDoc results were transmitted to the secured web portal. Eighteen attempts to measure and transmit an IBDoc measurement failed for various reasons, including application dysfunction, slow adjustment of focus when scanning the test cassette, or being too much in a hurry to await the test result. The hospital laboratory received 138 CALEX valve extraction devices and 170 screw-top containers. Median transport time was 2 (range, 0–7) days, and 82% of samples arrived in the hospital laboratory within 72 hours after collection (Supplementary Figure 1).

IBDoc vs ELISA


We compared IBDoc and ELISA measurements in 152 paired samples. In Figure 3A we present a Bland-Altman plot with 124 measurements situated in the lower calprotectin range ( $\leq 500 \mu\text{g/g}$ ) and 28 measurements in the higher calprotectin range ( $> 500 \mu\text{g/g}$ ). We found 81% (100 of 124) and 64% (18 of 28) of IBDoc measurements were within predefined limits of agreement in respectively the lower and higher calprotectin range. The mean difference (IBDoc minus ELISA) was  $-1.7 \mu\text{g/g}$  in the lower range and  $-52 \mu\text{g/g}$  in the higher range.

Passing-Bablok regression analysis showed a slope of 0.80 (95% confidence interval (CI), 0.72–0.88) with an

**Table 1.** Patient Demographics

	n	Stool samples	Median calprotectin (IQR) ( $\mu\text{g/g}$ ) <sup>a</sup>
<b>Age</b>			
- Children (<18 y of age)	19	58	40 (40–198)
- Adults ( $\geq 18$ y of age)	82	94	195 (69–588)
<b>Disease activity during stool sampling<sup>b</sup></b>			
- Symptomatic disease	Not applicable	50	445 (199–1010)
- Asymptomatic disease	Not applicable	84	47 (40–150)
- Unknown	Not applicable	18	420 (89–713)

IQR, interquartile range.  
<sup>a</sup>Measured with enzyme-linked immunosorbent assay.  
<sup>b</sup>Disease activity, as assessed by the Physician's Global Assessment, was reported when the interval between stool sampling and face-to-face encounter with the doctor was shorter than 1 month.



**Figure 3.** Bland-Altman plot showing difference against mean. (A) IBDoc and (enzyme-linked immunosorbent assay (ELISA) measurements. (B) IBDoc and Quantum Blue measurements. The pink zone corresponds with our predefined limits of agreement, which were arbitrary set at  $\pm 100 \mu\text{g/g}$  for the lower calprotectin range, and  $\pm 200 \mu\text{g/g}$  for the higher range. The outer lines correspond with the 95% limits of agreement (SD, 1.96).


intercept of 45.2 (95% CI, 10.9–79.6) and  $R^2$  of 0.72. Spearman's rank correlation coefficient was 0.85 ( $P < .001$ ).

The concordance between IBDoc and ELISA readings in each of the 3 FC ranges used in our clinical practice is presented in Figure 4. A total of 108 of 152 test pairs (71%) were concordant. Discordant test pairs leading to overt misinterpretation of disease activity (ie, calprotectin  $>500 \mu\text{g/g}$  with one method and  $<250 \mu\text{g/g}$  with the other) were observed in 6 of 152 stool samples (4%). Two of 6 discordant test pairs, depicted in the right lower corner of Figure 4, were caused by 1 participant who did not observe the advised incubation time. As a consequence, detachment of fecal material from the sampling grooves was incomplete. Stool consistency, transport time, age of participant (adult or child), and

type of smartphone were not clearly related to discordant results (data not shown). The concordance between IBDoc and ELISA reading for other frequently used dichotomous cutoff values is presented in Supplementary Table 3.

### IBDoc vs Quantum Blue

We compared patient-performed IBDoc smartphone readings and Quantum Blue readings by laboratory staff in 138 pairs of the same extraction fluid and show the corresponding Bland-Altman plot in Figure 3B. In the lower calprotectin range 95 of 104 (91%) IBDoc readings were within predefined limits of agreement, and in the higher ranges 24 of 34 IBDoc results (71%). The mean



**Figure 4.** Scatterplot showing calprotectin readings with IBDoc against enzyme-linked immunosorbent assay (ELISA) method. Concordance is defined as calprotectin levels in the same category (<250, 250–500, >500 µg/g) for both IBDoc and ELISA.

difference (IBDoc minus Quantum Blue) was  $-16$  µg/g in the lower range and  $-84$  µg/g in the higher range. Passing-Bablok regression analysis showed a slope of 0.85 (95% CI, 0.79–0.91) with an intercept of 12 (95% CI, 16–40) and  $R^2$  of 0.84. Spearman's rank correlation coefficient was 0.94 ( $P < .001$ ).

#### Self-Reported Usability

Sixty-three participants returned the questionnaire about the usability of the home test (response rate, 62%). A total of 87% of the respondents were of the opinion that the test was not difficult to perform. Holding

the smartphone in the right position to scan the test cassette was perceived as the most difficult step in the home test, and 97% of the respondents were interested in using the home test in the future.

## Discussion

#### Summary of Main Findings

The results show that the majority of calprotectin measurements performed at home with a lateral flow immunoassay and smartphone reader agreed sufficiently with the ELISA-based quantification of calprotectin in the

hospital laboratory, provided that calprotectin levels are below 500  $\mu\text{g/g}$ . In the higher calprotectin range a substantial proportion of pairs exceeded the predefined limits of agreement ( $\pm 200$   $\mu\text{g/g}$ ). Furthermore, we showed that the smartphone reader used by patients at home performed as good as the point-of-care Quantum Blue reader in the hospital.

Additional benefits of the home test include a reduction of the burden on hospital laboratory resources and a more patient-friendly sampling technique (with a pin instead of a spatula).<sup>12</sup>

### Comparisons With Existing Literature

To the best of our knowledge, this is the first study that compared the performance of the FC home test with both a point-of care test (Quantum Blue) using the same extraction fluid and the ELISA test.

In 2010 a Danish research team first described the use of a lateral flow device that could be read by a tabletop scanner connected to a computer with special software (CALPRO Inc, Oslo, Norway).<sup>13</sup> In the same paper it was shown that the lateral flow device could also be analyzed by taking a picture with a mobile phone and sending it to a server for evaluation. Both methods showed acceptable agreement compared with ELISA, but in this study the tests were carried out by an experienced laboratory technician who used the same extracted sample for all 3 methods. The same group recently reported the results of a study comparing long distance reading of a lateral flow technique from a different manufacturer (CalproSmart, Calpro AS, Lysaker, Norway) with ELISA.<sup>14</sup> They found a significant but lower Spearman rank correlation compared with our *IBDoc* results ( $r = 0.67$  vs  $r = 0.85$ ). The reader used in this study covered a measurable range of calprotectin from 30 to 600  $\mu\text{g/g}$ , and as a consequence of this smaller range the maximum difference that could be measured between the lateral flow test and ELISA was 570  $\mu\text{g/g}$ , compared with 960  $\mu\text{g/g}$  in our study. Major disadvantage in the Danish study included the use of a single type of smartphone for standardization purposes, whereas we included measurements from 16 different types of validated smartphones.

### Limitations of the Study

There are some limitations in our study that need to be addressed. First, the study participants were patients with a suitable smartphone and interest in home testing, rather than random IBD patients. We might have included a sample of patients with higher socioeconomic status and better education than others. Second, we observed a median delay of 2 days between *IBDoc* home testing and arrival of stool in our hospital, which could have influenced the agreement between the results. A recent study on the stability of calprotectin in fresh stool

showed no significant difference in concentrations between samples kept at room temperature for 1–3 days, but between 3 and 7 days a mean decrease of 28% was found.<sup>15</sup> In our study 82% of fresh stool samples arrived at the hospital laboratory within 3 days, and none more than 7 days after collection. With the introduction of home extraction and reading potential degradation of calprotectin in send in stool samples will no longer be an issue of importance.

### Implications for Clinical Practice

The evidence base for repeated FC testing in asymptomatic patients aimed at early recognition of disease exacerbation is accumulating.<sup>5</sup> Simultaneously, the number of telemonitoring initiatives for IBD care is rising.<sup>16–19</sup> Calprotectin home monitoring with a smartphone fits perfectly in the current spirit of the times and is another important step toward patient-centered care.<sup>20</sup> Whether FC home testing is cost effective should be evaluated in future studies. The actual price for *IBDoc* tests is approximately €30, compared with approximately €41 per ELISA test (which includes labor and equipment costs).

When repeated calprotectin home testing is implemented it is important to realize that the total variation between successive measurements can be influenced by biological variation (fluctuations within same subject), preanalytical variation (differences in collection technique, transport, storage, and handling of stool), and analytical variation (differences in precision of assay). In our study, taking too little time for the extraction process explained 2 of 6 discordant test pairs. Technical competence is not only an important element of training for hospital based laboratory technicians, but also for patients who wish to use a point-of-care calprotectin test at home. We therefore recommend to train interested patients in a skills lab until proficiency criteria have been met.<sup>21</sup>

### Conclusions

We found sufficient agreement between the home-used lateral flow test and the hospital-based ELISA test in the lower ranges of calprotectin to use this new test for telemonitoring of patients with asymptomatic IBD. In line with recent literature about FC monitoring, we suggest that confirmation of elevated *IBDoc* readings is done before therapy adjustment is considered.<sup>1,22</sup>

### Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Clinical Gastroenterology and Hepatology* at [www.cghjournal.org](http://www.cghjournal.org), and at <http://dx.doi.org/10.1016/j.cgh.2017.06.007>.



## References

1. Theede K, Holck S, Ibsen P, et al. Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis. *Inflamm Bowel Dis* 2016;22:1042–1048.
2. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. *Inflamm Bowel Dis* 2012;18:2218–2224.
3. Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. *Am J Gastroenterol* 2015;110:802–819.
4. Lin JF, Chen JM, Zuo JH, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. *Inflamm Bowel Dis* 2014;20:1407–1415.
5. Heida A, Park KT, van Rhee PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2017;23:894–902.
6. Diederik K, Hoekman DR, Leek A, et al. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission. *Aliment Pharmacol Ther* 2017;45:951–960.
7. Manceau H, Chicha-Cattoir V, Puy H, et al. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. *Clin Chem Lab Med* 2017;55:474–483.
8. Coorevits L, Baert FJ, Vanpoucke HJM. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. *Clin Chem Lab Med* 2013;51:825–831.
9. Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue® rapid test for faecal calprotectin. *Ann Clin Biochem* 2012;49:55–58.
10. Bland M. How can I decide the sample size for a study of agreement between two methods of measurement? 2004. Available at: [http://www-users.york.ac.uk/~mb55/meas/size\\_meth.htm](http://www-users.york.ac.uk/~mb55/meas/size_meth.htm). Accessed July 1, 2015.
11. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986;1:307–310.
12. Heida A, Dijkstra A, Dantuma SK, et al. A cross-sectional study on the perceptions and practices of teenagers with inflammatory bowel disease about repeated stool sampling. *J Adolesc Heal* 2016;59:479–481.
13. Elkjaer M, Burisch J, Voxen Hansen V, et al. A new rapid home test for faecal calprotectin in ulcerative colitis. *Aliment Pharmacol Ther* 2010;31:323–330.
14. Vinding KK, Elsberg H, Thorkilgaard T, et al. Fecal calprotectin measured by patients at home using smartphones—a new clinical tool in monitoring patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2016;22:336–344.
15. Lasson A, Stotzer PO, Ohman L, et al. The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis. *J Crohn's Colitis* 2015;9:26–32.
16. Huang VW, Reich KM, Fedorak RN. Distance management of inflammatory bowel disease: Systematic review and meta-analysis. *World J Gastroenterol* 2014;20:829–842.
17. Heida A, Dijkstra A, Groen H, et al. Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. *Trials* 2015;16:271.
18. Pedersen N, Elkjaer M, Duricova D, et al. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn's disease. *Aliment Pharmacol Ther* 2012;36:840–849.
19. Elkjaer M, Shuhaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided “Constant-care” approach. *Gut* 2010;59:1652–1661.
20. Richards T, Coulter A, Wicks P. Time to deliver patient centred care. *BMJ* 2015;350:h530.
21. Grantcharov TP, Reznick RK. Teaching procedural skills. *BMJ* 2008;336:1129–1131.
22. De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. *Inflamm Bowel Dis* 2013;19:2111–2117.
23. Bühlmann Laboratories AG. IBDoc Calprotectin Test. Instructions for use. 2015. Available at: [http://www.ibdoc.net/wp-content/uploads/2014/06/LF-IBDOC8\\_IFU\\_EN\\_V2.0.pdf](http://www.ibdoc.net/wp-content/uploads/2014/06/LF-IBDOC8_IFU_EN_V2.0.pdf). Accessed July 10, 2017.

### Reprint requests

Address requests for reprints to: Patrick F. van Rhee, MD, PhD, University of Groningen, University Medical Centre Groningen, Department of Paediatric Gastroenterology, Hepatology and Nutrition, Internal Code CA 31, PO Box 30001, 9700 RB Groningen, the Netherlands. e-mail: [p.f.van.rheenen@umcg.nl](mailto:p.f.van.rheenen@umcg.nl); fax: +31 50 3611671.

### Acknowledgments

The authors would like to thank all participants and their treating physicians and furthermore we would like to thank the laboratory technicians working at the department of laboratory medicine in the University Medical Center Groningen for the analysis of the Quantum Blue and ELISA results. Part of this work was presented at the 2017 ECCO Congress in Barcelona, Spain, and the 2017 DDW Conference in Chicago, Illinois.

### Conflicts of interest

The authors declare no conflicts.

### Funding

This work was supported by Bühlmann Laboratories AG, manufacturer of the IBDoc home test, Quantum Blue rapid test, and the fCAL ELISA assay used in this study. Bühlmann did not have a role in the design, execution, analyses, and interpretation of the data, or in the decision to submit the results.

## Supplementary Material

**Supplementary Table 1.** IBDoc Validated Smartphones at the Time of the Research Project

Validated smartphone types:	Number of readings in this study:
<b>iPhone:</b>	
- 4S	12 (8%)
- 5	27 (18%)
- 5c	4 (3%)
- 5s	17 (11%)
- 6	17 (11%)
- 6 plus	7 (5%)
- 6s	2 (1%)
- iPod touch 5 <sup>th</sup> generation	0
<b>HTC:</b>	
- One	0
<b>HUAWEI:</b>	
- P8 lite	1 (1%)
<b>SAMSUNG:</b>	
- GALAXY S3	14 (9%)
- GALAXY S4	16 (11%)
- GALAXY S5	16 (11%)
- GALAXY S5 mini	2 (1%)
- GALAXY S6	7 (5%)
- GALAXY A3	0
- GALAXY A5	0
- GALAXY CORE PRIME LTE	0
<b>SONY</b>	
- Xperia Z3 compact	1 (1%)
- Xperia Z3 compact	1 (1%)
<b>LG</b>	
- G4	0
- G3	0

## Supplementary Methods and Results: Quality assessment

**Method:** We prepared three homogenized stool pools representing a low, middle and high range calprotectin level (respectively 105  $\mu\text{g/g}$ , 186  $\mu\text{g/g}$ , and 507  $\mu\text{g/g}$ ). We then prepared low, middle and high range CALEX extraction fluids. Thereafter, we performed 10 readings of the same test cassette at one level, readings of 10 test cassettes loaded with one extract (from the 3 pools), and readings of 10 test cassettes loaded with 10 different extracts (from the 3 pools).


**Results:** Sample reproducibility results of both IBDoc and Quantum Blue are presented in the table below:

**Supplementary Table 2.** Coefficients of Variation in IBDoc Smartphone Readings and Quantum Blue Readings

	IBDoc	Quantum Blue
<b>Variation in 10 readings of the same test cassette</b>	4%	6%
<b>Variation in readings of 10 test cassettes loaded with one extract</b>		
Low-range calprotectin level ( $\pm 105 \mu\text{g/g}$ )	11%	4%
Middle-range calprotectin level ( $\pm 186 \mu\text{g/g}$ )	16%	11%
High-range calprotectin level ( $\pm 507 \mu\text{g/g}$ )	10%	16%
<b>Variation in readings of 10 test cassettes loaded with 10 different extracts</b>		
Low-range calprotectin level ( $\pm 105 \mu\text{g/g}$ )	17%	23%
Middle-range calprotectin level ( $\pm 186 \mu\text{g/g}$ )	18%	19%
High-range calprotectin level ( $\pm 507 \mu\text{g/g}$ )	25%	10%

**Supplementary Table 3.** Concordance Between IBDoc and ELISA Calprotectin Result for Frequently Used Dichotomous Cutoff Values

	Concordant + (IBDoc ↑; ELISA ↑)	Concordant - (IBDoc ↓; ELISA ↓)	Discordant (IBDoc ↓; ELISA ↑)	Discordant (IBDoc ↑; ELISA ↓)
Cutoff 50 µg/g	90 (59%)	45 (30%)	8 (5%)	9 (6%)
Cutoff 100 µg/g	69 (45%)	63 (41%)	10 (7%)	10 (7%)
Cutoff 150 µg/g	61 (40%)	74 (49%)	9 (6%)	8 (5%)
Cutoff 200 µg/g	50 (33%)	84 (55%)	8 (5%)	10 (7%)
Cutoff 250 µg/g	41 (27%)	91 (60%)	9 (6%)	11 (7%)
Cutoff 300 µg/g	34 (22%)	102 (67%)	8 (5%)	8 (5%)



**Supplementary Figure 1.** Overview of transport time.